[New York City, NY], March 9, 2026 – R1, the leader in healthcare revenue management, and Heidi, the leading AI-powered care partner, today announced a strategic partnership. Together, R1 and Heidi ...

Financing and global licensing deal to accelerate phase 2b development of AP306 R1 Therapeutics has launched with an oversubscribed $77.5 million Series A financing and an exclusive global licence to ...

Rivian is gearing up to launch the highly anticipated R2 on March 12, but it looks like they’re also planning to trim the R1 lineup. This is unfortunate, but the company sent out a rather ominous ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company looks to grow from ...

Series A co-led by Abingworth, DaVita Venture Group, and F-Prime with participation from Curie.Bio, SymBiosis, and U.S. Renal Care Partnership with Alebund Pharmaceuticals to gain exclusive global ...

March 17 (Reuters) - R1 Therapeutics said on Tuesday it had launched operations with a $77.5 million Series A funding round and an exclusive license to develop and commercialize a drug for high ...

REDWOOD CITY, Calif., March 17, 2026 (GLOBE NEWSWIRE)-- R1 Therapeutics, Inc (“R1”), a clinical-stage biopharmaceutical company focused on the development of first-in-class therapies for patients with ...

March 17 (Reuters) - R1 Therapeutics said on Tuesday it had launched operations with a $77.5 million Series A funding round and an exclusive license to develop and commercialize a drug for high ...

A high-level overview of Large Cap Value Fund CL R1 (WTLRNX) stock. View (WTLRNX) real-time stock price, chart, news, analysis, analyst reviews and more.

There is no recent news for this security. Got a confidential news tip? We want to hear from you. Sign up for free newsletters and get more CNBC delivered to your ...